US2019134216A1PendingUtilityA1
Anti-egfr antibodies and antibody drug conjugates
Est. expiryMar 21, 2034(~7.6 yrs left)· nominal 20-yr term from priority
A61P 43/00A61P 35/00C07K 2317/24C07K 2317/21A61K 47/6847C07K 2317/622C07K 2317/565C07K 2317/76C07K 2317/73A61K 47/6889C07K 16/2863C07K 16/30C07K 14/00C07K 16/3053A61K 47/6865A61K 2039/505C07K 2317/92C07K 2317/34A61K 47/6857A61K 47/6849C07K 16/3023A61K 47/6863C07K 16/3046A61K 47/6851C07K 2317/56A61K 47/6811A61K 47/6803A61K 2121/00A61K 47/68035A61K 47/68033A61K 47/68031
66
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
Claims
exact text as granted — not AI-modified1 . An anti-human epidermal growth factor receptor (anti-hEGFR) antibody comprising a heavy chain CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO: 22, a heavy chain CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO: 11, and a heavy chain CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO: 81; and a light chain CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO: 31, a light chain CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO: 30, and a light chain CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO: 29, wherein the antibody is an IgG isotype.
Join the waitlist — get patent alerts
Track US2019134216A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.